Clinical outcome of anti-PD-1/PD-L1 therapy was shown to correlate with MHC class II positivity in a unique subset of melanoma cells (typically MHC class II is expressed only on immune cells in solid tumors), as well as increased CD4+ and CD8+ TILs in melanoma patients (280). The gene discussed is PDCD1; the disease is melanoma.